NEW YORK (GenomeWeb) – Cantor Fitzgerald today upgraded shares of Rosetta Genomics to a Buy rating on the company's acquisition of PersonalizeDx

Analyst Sung Ji Nam upgraded Rosetta's shares from a previous Hold rating and increased its price target to $5.50 per share from an earlier target of $4. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.